Abstract: The present invention relates to the use of a combination of a wound-rinsing solution and cold atmospheric plasma for treating wounds. The present invention further relates to a method for treating wounds, comprising rinsing the wound with a wound solution and treating the wound with cold atmospheric plasma.

Abstract: The invention relates to a single photon detector device for detecting an optical signal comprising an optical fiber and at least one nanowire, wherein the optical fiber comprises a core area and a cladding area and is designed to conduct the optical signal along an optical axis, wherein, with respect to the optical axis, a first area of the optical fiber is an entrance area for the optical signal and a second area of the optical fiber is a detector area, and wherein the nanowire becomes superconducting at a predetermined temperature and is designed in the superconducting state to generate an output signal as a function of the optical signal. It is provided that in the detector area of the optical fiber the nanowire extends essentially along the optical axis of the optical fiber. A single photon detector device is thus provided which has a simple structure, a high efficiency, a high detection rate and a high spectral bandwidth.

Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.

Abstract: The invention relates to an electrolyte arrangement for a cell having at least one anode (1) and at least one cathode (3) comprising at least three superposed layers (2.1, 2.2, 2.3), wherein the middle layer (2.2) comprises a porous electrically nonconductive structure, and wherein a layer of a polymer-based electrolyte (2.1, 2.3) is arranged on both opposite sides of the porous electrically nonconductive structure, wherein at least one of the superposed layers (2.1, 2.2, 2.3) contains a ceramic material, wherein the ceramic material of the middle layer (2.2) is selected from metal ion-conductive ceramic material, a ceramic material which does not conduct metal ions, and/or mixtures thereof, and the ceramic material of the polymer-based electrolyte layer(s) (2.1, 2.3) is a metal ion-conductive ceramic material.

Abstract: The present invention relates to a novel method for producing fluorinated cycloaliphatic compounds from the analogous aromatic compounds by hydrogenation with an Rh-carbene catalyst system.

Abstract: The present invention relates to mutants of S100A12 having at least one mutation in the high-affinity calcium binding hand or the low-affinity calcium binding hand or the zinc binding region. The present invention also relates to methods of detecting S100A12 dimers in a sample as well as methods of diagnosis using the S100A12 mutant of the invention, as well as to diagnostic compositions and kits comprising such an S100A12 mutant. The present invention further relates to a method of generating an antibody that specifically binds to an S100A12 dimer using the S100A12 mutant of the invention, as well as to an antibody that specifically binds to an S100A12 dimer.

Abstract: The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in combination with inventive polymers, i.e. light-cleavable polymers, that can be used as photosensitizer compositions for a wide range of light irradiation treatments such as photodynamic therapy of cancer, infections and other diseases. The dye derivatives may either be adsorbed on, or incorporated in, or attached to specific polymers, which as well form part of the invention.

Abstract: It is an object of the present invention to provide methods for assessing the efficacy of a remote ischemic preconditioning procedure though the measurement of urinary TIMP-2 and IGFBP7 concentrations.

Abstract: The present invention relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunomodulatory domains thereof, for use in immunotherapy. The present invention further relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunomodulatory domains thereof, for delivering cargo molecules into eukaryotic cells.

Abstract: The present invention relates to a novel method for producing fluorinated cycloaliphatic compounds from the analogous aromatic compounds by hydrogenation with an Rh-carbene catalyst system.

Abstract: The invention relates to the use of compounds according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives, as additives in electrolytes for electrochemical energy sources such as lithium-ion-batteries, and compounds containing electrolytes according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives.

Abstract: The present invention relates to the combined use of NO-donors for the treatment, prevention and/or amelioration of disturbances of the cerebral macro- and microcirculation which disturbances cause cerebrovascular spasms (CVS) and/or malperfusion of brain parenchyma caused by blood vessel and blood flow dysregulation.

Abstract: The invention relates to the use of compounds according to general formula (1), in particular 1,4,2-dioxoazol-5-on-derivatives, as additives in electrolytes for electrochemical energy sources such as lithium-ion-batteries, and compounds containing electrolytes according to general formula (1), in particular, 1,4,2-dioxoazol-5-on-derivatives.

Abstract: The present invention is related to NDP-MSH or pharmaceutically acceptable salts thereof for therapeutic and/or prophylactic therapeutic treatment of inflammatory and/or neurodegenerative disorders of the CNS or multiple sclerosis. The present invention is further related to pharmaceutical compositions and a kit comprising NDP-MSH or pharmaceutically acceptable salts thereof.

Abstract: In a device for generating output laser pulses having a tunable central wavelength, based on parametric amplification, a laser system is to be provided that has less complexity, but that nevertheless provides great tunability for the wavelength, permits rapid switching of the wavelength, and allows the spectral bandwidth of the emitted pulses to be adjusted. This is attained in that for adjustability of the bandwidth of the output laser pulses, an optical device is provided that is designed to influence the spectral phase of the pump pulses as a function of the spectral phase of the seed pulses.

Abstract: The present invention relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunomodulatory domains thereof, for use in immunotherapy. The present invention further relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunomodulatory domains thereof, for delivering cargo molecules into eukaryotic cells.

Abstract: The present invention relates to an in vitro method for diagnosing an acute or relapsing phase of inflammatory bowel disease as well as a method for treating the acute or relapsing phase of inflammatory bowel disease. In addition, the present invention relates to a medicament for use in the treatment of inflammatory bowel disease. Further comprised by the present invention is the use of a nucleic acid molecule of SEQ ID NO: 1 or 2 for monitoring the progression of said disease and in vitro diagnosis of an acute or relapsing phase of said disease. Also a device for the diagnosis of said disease and kits for performing the method of the present invention are envisaged by the present invention.

Abstract: The present invention is related to silicon nanoparticles, a pharmaceutical composition comprising silicon nanoparticles, a method for synthesis of the silicon nanoparticles and their use for in vivo diagnostics, visualization of drug delivery or staining of cells, biological processes or pathways. The silicon nanoparticles are characterized that they comprise a silicon core of a size of 1 to 10 nm and are terminated with allylamine or poly(allylamine) comprising up to 10 allylamine groups.

Abstract: Described are methods and compositions for evaluating the relapse risk n subjects having an inflammatory bowel disease (IBD). Some embodiments include selecting a treatment for an evaluated IBD relapse risk in a subject.

Abstract: The present invention relates to a method and a device for providing a current of spin-polarized electrons. More particularly, the present invention is suited for use in spin electronics or detection of spin-polarized electrons.